Skip to main content
Oreofe Odejide, MD, Oncology, Boston, MA

OreofeOOdejideMDMPH

Oncology • Boston, MA

Hematologic Oncology

Assistant Professor of Medicine, Harvard Medical School Physician, Dana-Farber Cancer Institute

Join to view full profile

Dr. Odejide is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Odejide's full profile

Already have an account?

  • Office

    450 Brookline Avenue
    Boston, MA 02215
    Phone+1 617-632-3470
    Fax+1 617-632-5175

Summary

  • Dr. Oreofe Odejide is an oncologist in Boston, MA and is affiliated with multiple hospitals in the area, including Dana-Farber Cancer Institute and Brigham and Women's Hospital. She received her medical degree from Howard University College of Medicine and has been in practice 9 years. She specializes in hematologic oncology.

Education & Training

  • Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer Institute
    Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2011 - 2014
  • Brigham and Women's Hospital
    Brigham and Women's HospitalResidency, Internal Medicine, 2008 - 2011
  • Howard University College of Medicine
    Howard University College of MedicineClass of 2008
  • Harvard T.H Chan School of Public Health
    Harvard T.H Chan School of Public HealthMPH, Clinical Effectiveness

Certifications & Licensure

  • MA State Medical License
    MA State Medical License 2011 - 2025
  • ME State Medical License
    ME State Medical License 2022 - 2025
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Hematology
  • American Board of Internal Medicine Medical Oncology

Clinical Trials

Publications & Presentations

PubMed

Abstracts/Posters

  • Utilization and Early Discontinuation of First-Line Ibrutinib for Patients with Chronic Lymphocytic Leukemia Treated in the Community Oncology Setting in the United St...
    Oreofe O. Odejide, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Lectures

  • Moving Forward When It Is Time to Stop 
    ASCO Annual Meeting 2019 - Chicago, IL - 6/2/2019
  • Rituximab/Bendamustine and Rituximab/Cytarabine (RB/RC) Induction Chemotherapy for Transplant-Eligible Patients with Mantle Cell Lymphoma: A Pooled Analysis of Two Pha... 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • PD-1 Blockade with Pembrolizumab for Classical Hodgkin Lymphoma after Autologous Stem Cell Transplantation 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

  • Share on Twitter Share on Facebook Share on LinkedIn Olanzapine Reduces Nausea and Improves Quality of Life for Patients with Cancer During Chemotherapy
    Share on Twitter Share on Facebook Share on LinkedIn Olanzapine Reduces Nausea and Improves Quality of Life for Patients with Cancer During ChemotherapySeptember 24th, 2024
  • Study Finds Fewer Blood Cancer Patients Get Hospice Care
    Study Finds Fewer Blood Cancer Patients Get Hospice CareMay 22nd, 2017
  • Genetically Modifying T-cells Cuts Blood Cancer Progression by 74%, Trial Finds
    Genetically Modifying T-cells Cuts Blood Cancer Progression by 74%, Trial FindsJune 6th, 2023
  • Join now to see all

Professional Memberships

Dr. Oreofe Odejide, Dr. Oreofe Odejide, MD, Dr. O Odejide, Dr. Oreofe O Odejide